Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer Study 2 (CISTO2) has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO2 is to conduct a large prospective study that directly compares the impact of bladder sparing therapies versus bladder removal in recurrent high-grade NMIBC patients on financial toxicity, clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby dorosłe (powyżej 18 lat).
- •Potwierdzony rak pęcherza moczowego, który nie nacieka mięśni.
- •Rak pęcherza o wysokim stopniu złośliwości, odnotowany w badaniach histopatologicznych.
- •W ciągu ostatniego roku pacjent otrzymywał leczenie do pęcherza lub inne leki.
✗ Disqualifies
- •Istnienie innych typów raka pęcherza, np. plazmocytowy lub drobnokomórkowy.
- •Wcześniejsze leczenie operacyjne lub radioterapia z powodu raka pęcherza.
- •Rak pęcherza, który nacieka mięśnie, lub rak, który dał przerzuty.
- •Obecność raka dróg moczowych poza pęcherzem (np. moczowody, miedniczki nerkowe), który nie był leczony lub był leczony mniej niż 2 lata temu.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Locations (6)
H. Lee Moffitt Cancer Center & Research Institute
Tampa, United States
University of Iowa
Iowa City, United States
University of North Carolina
Chapel Hill, United States
The Ohio State University
Columbus, United States
Vanderbilt University Medical Center
Nashville, United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Sung Min Kim
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.